A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
In this open-label multicenter study the long-term effect of Pegasys monotherapy on
pharmacodynamic HBV-related markers will be investigated in patients with chronic hepatitis
B. Eligible patients will have completed treatment on another donor protocol (e.g. PP22512)
and will receive Pegasys at an appropriate dose based on the standard of care (180mcg sc once
weekly) for up to 48 weeks. Target sample size is <100.